Imunon, Inc. (IMNN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.84
- As of
Kresmion compiles this page from IMNN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Imunon, Inc. (IMNN): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full IMNN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IMNN on one page. Preview it with sample data, then open it live with a free account.
Preview the IMNN dossierActive events for IMNN
- mediumEarnings above estimates
Q2-2026: Beat consensus by 42.8%, EPS $-0.54 vs $-0.9445 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 55.5% - EPS $-1.86957 vs $-4.2042 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 37.0% - EPS $-1.16 vs $-1.8413 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 66.2% - EPS $-1.99 vs $-1.1975 estimate
- mediumEarnings above estimates
Q1-2026: Beat consensus by 25.8% - EPS $-0.84 vs $-1.1322 estimate
FREE, NO ACCOUNT
Every event on IMNN, as it fires
New filings, 13F moves and cross asset events on IMNN land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, IMNN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
IMNN's 10-Q filed Aug 11, 2026 states:
Such conditions raise substantial doubts about the Company's ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on IMNN
IMNN against its peers
IMNN's return on equity of -205.3% ranks in the 38th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | IMNN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 405000 | n/a | 17 |
| Gross margin | n/a | 20.4% | n/a | 7 |
| Operating margin | n/a | -514.9% | n/a | 12 |
| Net margin | n/a | -465.4% | n/a | 13 |
| Return on equity | -205.3% | -135.5% | 38 | 19 |
Peers (23): EVGN, CNSY, CANF, NIKI, CDIO, AZTR, OTLC, CELZ, SNGX, RVPH, XBIO, SKYE, OSRH, PULM, APTOF.D, AAGH, JAGX, PCSA, GRI, NCNA, BGMS, PMCB, LGVN. Left out: ADXN (period gap), LIANY (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (IMNN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in IMNN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on IMNN in the last 180 days.
Upstream: SEC EDGAR filings for IMNN
Kresmion, "Imunon, Inc. (IMNN) institutional holdings and SEC filings", data as of 2026-10-27, https://kresmion.com/research/IMNN. Upstream data: SEC EDGAR filings for IMNN.
Link to this data (HTML):
<a href="https://kresmion.com/research/IMNN">Imunon, Inc. (IMNN) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow IMNN on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to IMNN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.